×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSE:BMY

Bristol-Myers Squibb Stock Forecast, Price & News

$76.84
-0.16 (-0.21%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$75.77
$76.98
50-Day Range
$72.62
$79.98
52-Week Range
$53.22
$80.59
Volume
10.88 million shs
Average Volume
12.63 million shs
Market Capitalization
$163.60 billion
P/E Ratio
27.25
Dividend Yield
2.81%
Price Target
$74.27

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
3.3% Downside
$74.27 Price Target
Short Interest
Healthy
1.63% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.30
Upright™ Environmental Score
News Sentiment
0.20mentions of Bristol-Myers Squibb in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$7.09 M Sold Last Quarter
Proj. Earnings Growth
7.52%
From $7.58 to $8.15 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.43 out of 5 stars

Medical Sector

74th out of 1,428 stocks

Pharmaceutical Preparations Industry

24th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

Bristol-Myers Squibb logo

About Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

BMY Stock News Headlines

Zumiez, Tesla fall; Okta, Calavo Growers rise
Stocks that traded heavily or had substantial price changes Friday: Zumiez, Tesla fall; Okta, Calavo Growers rise
Brokerages Set Bristol-Myers Squibb (NYSE:BMY) PT at $74.27
Bristol-Myers Squibb: When Will The Correction End?
Bristol-Myers Squibb Stock: Downgrade To Hold Now
Bristol-Myers Is Melting-Up Again
Bristol-Myers Squibb (BMY) To Go Ex-Dividend on June 30th
Here's How to Treat Bristol-Myers Squibb's Charts
The 2 Best Sectors to Invest in Right Now
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
11012210
Employees
32,200
Year Founded
1887

Company Calendar

Ex-Dividend for 5/2 Dividend
3/31/2022
Last Earnings
4/29/2022
Dividend Payable
5/02/2022
Ex-Dividend for 8/1 Dividend
6/30/2022
Today
7/03/2022
Next Earnings (Confirmed)
7/27/2022
Dividend Payable
8/01/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$74.27
High Stock Price Forecast
$92.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
-3.3%
Consensus Rating
Hold
Rating Score (0-4)
2.45454545454545
Research Coverage
11 Analysts

Profitability

Net Income
$6.99 billion
Pretax Margin
15.45%

Debt

Sales & Book Value

Annual Sales
$46.39 billion
Cash Flow
$12.41 per share
Book Value
$16.22 per share

Miscellaneous

Outstanding Shares
2,129,060,000
Free Float
2,127,148,000
Market Cap
$163.60 billion
Optionable
Optionable
Beta
0.45

Social Links















Bristol-Myers Squibb Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Bristol-Myers Squibb stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
View analyst ratings for Bristol-Myers Squibb
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price forecast for 2022?

11 analysts have issued twelve-month target prices for Bristol-Myers Squibb's stock. Their BMY stock forecasts range from $49.00 to $92.00. On average, they expect Bristol-Myers Squibb's stock price to reach $74.27 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts' price targets for Bristol-Myers Squibb
or view top-rated stocks among Wall Street analysts.

How has Bristol-Myers Squibb's stock price performed in 2022?

Bristol-Myers Squibb's stock was trading at $62.35 at the beginning of the year. Since then, BMY shares have increased by 23.2% and is now trading at $76.84.
View the best growth stocks for 2022 here
.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Bristol-Myers Squibb
.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Wednesday, July 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) posted its quarterly earnings data on Friday, April, 29th. The biopharmaceutical company reported $1.96 EPS for the quarter, beating analysts' consensus estimates of $1.92 by $0.04. The biopharmaceutical company had revenue of $11.65 billion for the quarter, compared to the consensus estimate of $11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a trailing twelve-month return on equity of 48.37%. The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the business earned $1.74 EPS.
View Bristol-Myers Squibb's earnings history
.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, June 16th. Stockholders of record on Friday, July 1st will be paid a dividend of $0.54 per share on Monday, August 1st. This represents a $2.16 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Thursday, June 30th.
View Bristol-Myers Squibb's dividend history
.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb(NYSE:BMY) pays an annual dividend of $2.16 per share and currently has a dividend yield of 2.81%. Bristol-Myers Squibb has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Bristol-Myers Squibb is 76.60%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.50% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.
View Bristol-Myers Squibb's dividend history.

When did Bristol-Myers Squibb's stock split? How did Bristol-Myers Squibb's stock split work?

Bristol-Myers Squibb's stock split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $7.44-$7.74 for the period, compared to the consensus EPS estimate of $7.73. The company issued revenue guidance of -.

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb CEO Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among Bristol-Myers Squibb's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Chemung Canal Trust Co. (0.00%), Stonebridge Capital Management Inc. (0.00%) and Park National Corp OH (0.00%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Autenried Paul Von, Christopher S Boerner, David V Elkins, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Rupert Vessey, Sandra Leung and Terrie Curran.
View institutional ownership trends for Bristol-Myers Squibb
.

Which institutional investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and Stonebridge Capital Management Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last two years include Adam Dubow, Autenried Paul Von, Christopher S Boerner, David V Elkins, Giovanni Caforio, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Rupert Vessey, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb
or view top insider-selling stocks.

Which institutional investors are buying Bristol-Myers Squibb stock?

BMY stock was purchased by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co..
View insider buying and selling activity for Bristol-Myers Squibb
or or view top insider-buying stocks.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $76.84.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb (NYSE:BMY) has a market capitalization of $163.60 billion and generates $46.39 billion in revenue each year. The biopharmaceutical company earns $6.99 billion in net income (profit) each year or $2.82 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

Bristol-Myers Squibb employs 32,200 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?

The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More

When was Bristol-Myers Squibb founded?

Bristol-Myers Squibb was founded in 1887.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The official website for Bristol-Myers Squibb is www.bms.com. The biopharmaceutical company can be reached via phone at (212) 546-4000, via email at john.elicker@bms.com, or via fax at 212-546-4020.

This page (NYSE:BMY) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.